Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 13, 2006

View Archived Issues

R&D highlights from the UBS Global Life Sciences Conference in New York: Abraxis BioScience

Snapshots of studies of the antibiotic efficacy of CS-023

FK-228 shows activity in ongoing metastatic hormone refractory prostate cancer trial

ZIO-101 demonstrates anticancer activity in patients with advanced disease

Promising activity seen with DJ-927 in advanced breast cancer

Biovitrum and Synphora sign agreement on JB-991 for psoriasis

Nautilus files IND for Belerofon

OPi and Vaccinex sign licensing agreement for anti-IL-6 antibody

Final efficacy results of GENASIS trial

MGA-031 awarded orphan drug status for recent-onset type 1 diabetes mellitus

Phase I study begins for next-generation anticoagulant M-118

Preparations for phase II study of NeuroVax in relapsing-remitting MS

DOV outlines new strategic direction

Phase I study evaluates CRS-100 in cancer patients with liver metastases

IMA-901 for renal cell cancer evokes immune responses in phase I study

European orphan drug status recommended for EndoTAG-1 in pancreatic cancer

In vivo efficacy of NXL-101 against multiresistant S. aureus

Ferrer present preclinical data on their candidate for dermal infections

Novel agents for pain, migraine, etc., imparted in recent patent literature

Novel wound-healing agents disclosed in recent Northwestern University patent

New compounds with potential in the treatment of neurological disorders reported

FDA requests additional phase III trial for Saforis

Avastin approved with chemotherapy for first-line treatment of NSCLC

Intercell begins regulatory process for Japanese encephalitis vaccine

R&D highlights from the UBS Global Life Sciences Conference in New York: Locus Pharmaceuticals

Orphan drug designation for 4975 in interdigital neuroma

Supplemental NDA filed for Advair Diskus in COPD

Riquent MAA to be withdrawn, with plans for resubmission

Researchers identify KALRN as novel CAD susceptibility gene

HLA-C identified as second susceptibility locus for multiple sclerosis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 16, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...